InvestorsHub Logo
Followers 2
Posts 188
Boards Moderated 0
Alias Born 01/18/2019

Re: None

Monday, 06/10/2019 7:22:13 AM

Monday, June 10, 2019 7:22:13 AM

Post# of 425931

AZN has no cardiovascular risk prevention IP..nor will they ever after the results of REDUCE-IT. -Biobillionaire



Charming handle. But, you are incorrect. AZN's patents covering Epanova are quite secure, and well written, unlike Amarin's patents covering Vascepa, which are weak and full of redundancies. There is nothing novel about ethyl ester EPA, especially not for the use of lowering trigs.



Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News